Early prediction of response to Vorinostat in an orthotopic rat glioma model (pages 1104–1111)
Li Wei, Samuel Hong, Younghyoun Yoon, Scott N. Hwang, Jaekeun C. Park, Zhaobin Zhang, Jeffrey J. Olson, Xiaoping P. Hu and Hyunsuk Shim
Version of Record online: 2 FEB 2012 | DOI: 10.1002/nbm.2776
During carcinogenesis, tumor suppressor genes can be silenced by aberrant histone deacetylation caused by histone deacetylase (HDAC). A major shortcoming of the use of HDAC inhibitors in the treatment of patients with brain tumors is the lack of reliable prognostic biomarkers. The current work describes a preclinical study for the development of MRS-based and histopathologic biomarkers, which correlate with the normalization of brain metabolism and function, and thus predict the therapeutic response to Vorinostat.